FDAsafety guidance66% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Novo Nordisk; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Obesity · GLP-1 Agonist
- Sub-indication
- General
Related signal: FDA Approves Supplemental Application for Wegovy (Semaglutide)